← Back
NeuroTrials.ai
Neurology Clinical Trial Database

RACECAT

Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas

Year of Publication: 2022

Authors: Natalia Pérez de la Ossa, Sònia Abilleira, Tudor G. Jovin, ..., for the RACECAT Trial Investigators

Journal: JAMA

Citation: JAMA. 2022;327(18):1782-1794.

Link: https://doi.org/10.1001/jama.2022.4404

PDF: https://jamanetwork.com/journals/jama/fullarticle/2791844


Clinical Question

In nonurban areas, does direct transport to a thrombectomy-capable center result in better 90-day outcomes vs transport to the closest local stroke center in patients with suspected LVO?

Bottom Line

Direct transport did not improve 90-day outcomes vs local stroke center transport (adjusted OR 1.03; 95% CI 0.82-1.29). Direct transport increased thrombectomy rates (48.8% vs 39.4%) but reduced IV tPA rates (47.5% vs 60.4%), suggesting these effects offset each other. Stopped early for futility.

Major Points

  • No difference in 90-day mRS: adjusted OR 1.03 (0.82-1.29). Stopped for futility at 2nd interim analysis.
  • Direct transport increased thrombectomy: 48.8% vs 39.4% (OR 1.46; 1.13-1.89).
  • But reduced IV tPA: 47.5% vs 60.4% (OR 0.59; 0.45-0.76).
  • Time trade-off: tPA delayed by 35 min (155 vs 120 min) but groin puncture shortened by 56 min (214 vs 270 min).
  • Mortality identical: 27.3% vs 27.2% (HR 0.96; 0.78-1.18).
  • 64.6% of local stroke center patients were emergently transferred for thrombectomy.
  • First RCT comparing mothership vs drip-and-ship in suspected LVO.
  • 1,401 randomized (cluster, spatial-temporal); Catalonia, Spain; 6 thrombectomy + 22 local centers.
  • No subgroup benefited from direct transport (age, sex, tPA eligibility, RACE score — all NS interaction).
  • Results reflect a high-performance Catalan system — may not generalize to systems with longer transfer times or lower baseline thrombectomy rates.

Design

Study Type: Multicenter, population-based, spatial-temporal cluster-randomized trial with blinded endpoint assessment

Randomization: 1

Blinding: Open-label; blinded 90-day mRS assessment by certified telephone assessors. Cluster randomized by 12-hour time slots, stratified by territory and day of week.

Enrollment Period: March 2017 to June 2020

Follow-up Duration: 90 days

Centers: 28

Countries: Spain (Catalonia)

Sample Size: 1401

Analysis: ITT (as-randomized). Ordinal logistic regression. Stopped for futility at 70% enrollment.


Inclusion Criteria

  • Functionally independent (prestroke mRS 0-2).
  • Suspected LVO: RACE Scale score 5-9.
  • EMS evaluation in nonurban area where primary referral was a local stroke center without thrombectomy.
  • Estimated arrival at thrombectomy center <7 hours after onset.
  • Transport time to thrombectomy center 20-180 minutes.

Exclusion Criteria

  • Unstable clinical status or coma requiring emergent life support.
  • Prestroke mRS >2.
  • RACE Scale <4.
  • Estimated arrival at thrombectomy center >7 hours from onset.

Baseline Characteristics

CharacteristicThrombectomy Center (N=482)Local Stroke Center (N=467)
Age median (IQR)77 (67-84)76 (66-84)
Female219 (45.4%)209 (44.8%)
Hypertension352 (73.5%)331 (72.4%)
Diabetes122 (25.5%)105 (23.0%)
AF120 (25.1%)129 (28.2%)
RACE Scale median (IQR)7 (6-8)7 (6-8)
NIHSS at hospital median (IQR)16 (9-20)16 (11-21)
LVO confirmed333 (69.1%)303 (64.9%)
Time onset to first hospital median (IQR)142 (100-231) min88 (61-145) min
Travel time >60 min to thrombectomy center270 (56.0%)254 (54.4%)

Arms

FieldDirect to Thrombectomy Center (Mothership)Control
InterventionDirect ground ambulance transport to thrombectomy-capable center, bypassing local stroke center. Modification only for clinical deterioration.Transport to closest local stroke center. If LVO confirmed or suspected (NIHSS ≥6), emergent transfer to thrombectomy center. 64.6% transferred; median door-in/door-out 78 min.
DurationSingle transport decision + 90-day follow-upSingle transport decision + 90-day follow-up

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Distribution of mRS at 90 days (ordinal shift, mRS 5+6 collapsed)PrimarymRS median 3 (IQR 2-5)mRS median 3 (IQR 2-5)NS (futility stopped)
IV alteplase administeredSecondary282/467 (60.4%)229/482 (47.5%)OR 0.59
Thrombectomy performedSecondary184/467 (39.4%)235/482 (48.8%)OR 1.46
Time onset to tPA medianSecondary120 min155 minDiff +34.5 min
Time onset to groin puncture medianSecondary270 min214 minDiff -56 min
Dramatic early response at 24hSecondary134/467 (28.7%)115/482 (23.9%)OR 0.76
90-day mortalityAdverse194/713 (27.2%)188/688 (27.3%)HR 0.96
Clinical worsening requiring intubationAdverse5/713 (0.7%)7/688 (1.0%)OR 1.45

Subgroup Analysis

No significant interactions: age (<80/≥80), sex, tPA eligibility, prestroke mRS, RACE score (5-7/8-9). Transport time analysis: no effect modification by estimated travel time (P interaction=0.47).


Criticisms

  • Results apply only to nonurban patients in a high-performance Catalan system with efficient drip-and-ship.
  • 44% of local stroke center patients had no vessel imaging at first hospital.
  • Stopped early for futility — may have been underpowered for subgroups.
  • Cluster randomization with inadvertent mismatch in first 350 patients.
  • Cannot establish transport time thresholds that might favor direct transport.
  • Workflow reflects European model with mandatory neurology contact — may not replicate elsewhere.

Funding

Fundació Ictus Malaltia Vascular via unrestricted grant from Medtronic (no role in trial).

Based on: RACECAT (JAMA, 2022)

Authors: Natalia Pérez de la Ossa, Sònia Abilleira, Tudor G. Jovin, ..., for the RACECAT Trial Investigators

Citation: JAMA. 2022;327(18):1782-1794.

Content summarized and formatted by NeuroTrials.ai.